Tenosynovial Giant Cell Tumor Market - Top Companies and Manufacturers

Companies Dominating the Tenosynovial Giant Cell Tumor Landscape

Abbisko Therapeutics
- Company Overview
- Business Planning
- Main Product Offerings
- Financial Execution
- Main Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis

Ammax Bio Inc.
HUTCHMED
SynOx Therapeutics Limited
Deciphera Pharmaceuticals Inc.
F. Hoffmann-La Roche Ltd
Novartis AG
Amgen Inc.
Celleron Therapeutics Limited
Takeda Pharmaceutical Company Limited.

Browse Key Market Insights with Data Illustration:

Tenosynovial Giant Cell Tumor Market Size Forecasts 2036

In the News

Abbisko Therapeutics declared that the newest results of the Phase Ib study of its CSF-1R inhibitor Pimicotinib (ABSK021) in curing patients with advanced tenosynovial giant cell tumor ("TGCT"), was published at the 2023 American Society of Clinical Oncology ("ASCO") yearly meeting that took place in Chicago, USA from June 2 to June 6, 2023.
Ammax Bio Inc. declared that the European Medicines Agency (EMA) has approved AMB-05X Priority Medicines (PRIME) designation for the cure of tenosynovial giant cell tumor (TGCT). AmMax Bio delivered positive Phase II information for the novel local management of AMB-05X in patients with TGCT at the Connective Tissue Oncology Society meeting in November 2022. The efficiency information across multiple clinical endpoints and a favorable protection profile support the possibility of AMB-05X as a best-in-class treatment for the therapy of TGCT irrespective of surgical reputability.

Frequently Asked Questions (FAQ)

The increasing cases of tenosynovial giant cell tumor diseases in almost all age groups people will majorly drive the market growth of the tenosynovial giant cell tumor market.

The market size of the tenosynovial giant cell tumor market is expected to get a CAGR of approximately 5% over the forecast period, i.e., 2024-2036.

The major players in the market are Abbisko Therapeutics, Ammax Bio Inc., HUTCHMED, SynOx Therapeutics Limited, Deciphera Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Amgen Inc., Celleron Therapeutics Limited, Takeda Pharmaceutical Company Limited., Daiichi Sankyo Company, Limited., Chugai Pharmaceutical Co., Ltd., CHEPLAPHARM Arzneimittel GmbH, Ono Pharmaceutical Co., Ltd.

The surgical procedure segment is anticipated to reap the largest market size by the end of 2036 and demonstrate substantial growth scopes.

The market in the North American region is expected to have the largest market share by the end of 2036 and provide more business opportunities in the future.

Tenosynovial Giant Cell Tumor Market - Top Companies and Manufacturers

Companies Dominating the Tenosynovial Giant Cell Tumor Landscape

Browse Key Market Insights with Data Illustration:

In the News

Frequently Asked Questions (FAQ)

What are the major factors driving the growth of the tenosynovial giant cell tumor market?

What would be the CAGR of the tenosynovial giant cell tumor market over the forecast period?

Who are the major players dominating the tenosynovial giant cell tumor market?

Which segment captures the largest market size in the treatment segment of the tenosynovial giant cell tumor market?

Which region will provide more business opportunities for the growth of the tenosynovial giant cell tumor market in the future?